Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.1500 |
Strike | 7.50 |
Expiry date | 2024-05-17 |
Day's range | 0.1000 - 0.1100 |
Contract range | N/A |
Volume | |
Open interest | 216 |
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.